| Literature DB >> 35875294 |
Mirza M A Baig1, Shayan A Irfan1, Anusha Sumbal1, Ramish Sumbal1, Sanjay Kumar2, Junaid Ahmad3, Nikhila Gandrakota4, Laila Tul Qadar1, Maida S Chaudhry5, Azka Feroz1, Muhammad Sheharyar Warraich6.
Abstract
The meta-analysis aimed to investigate the prevalence of gallstones (GS) in Inflammatory bowel disease (IBD), especially ulcerative colitis (UC). A systematic and thorough search was conducted on online electronic databases (PubMed/Medline, Cochrane Library, and Google Scholar) from the databases' inception to April 30th, 2022. Review Manager 5.4.1 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen) was used for all statistical analyses and forest plots. Only studies that met inclusion criteria were selected. The selected studies were pooled using a random-effect model and the results were reported in the odds ratio (OR) with their corresponding 95% confidence interval (CI). Ten studies met the final inclusion criteria and were analyzed. Patients with UC had significantly higher prevalence of GS than those in the control group (OR=1.67 [1.32-2.11]; p < 0.0001; I2=58%). There was also significant prevalence of GS in Crohn's disease (CD) than those in control group (OR=2.22 [1.82, 2.69]; p < 0.00001; I2=31%). Analysis also showed the prevalence of GS in studies conducted in Asia (OR=2.00 [1.48, 2.70]; p < 0.00001; I2=80%) and Europe (OR= 1.84 [1.32, 2.55]; p = 0.0003; I2=45%) compared to the control group. This study provided a conclusive answer to whether GS is significant in UC or not. Our meta-analysis provides a well-powered estimate that there is a prevalence of GS in UC. CD is also significantly associated with GS.Entities:
Keywords: crohn's disease; gallstones; inflmammtory bowel disease; prevalence; ulcerative colitits
Year: 2022 PMID: 35875294 PMCID: PMC9299396 DOI: 10.7759/cureus.26121
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Details of the search strategy
| Search Engine | Search Strategy |
| Pubmed/Medline | (("crohn*"[All Fields] AND ("disease"[MeSH Terms] OR "disease"[All Fields] OR "diseases"[All Fields] OR "disease s"[All Fields] OR "diseased"[All Fields])) OR "IBD"[All Fields] OR ("inflamm"[All Fields] AND ("bowel s"[All Fields] OR "bowell"[All Fields] OR "intestines"[MeSH Terms] OR "intestines"[All Fields] OR "bowel"[All Fields] OR "bowels"[All Fields]))) AND ("gallstones"[MeSH Terms] OR "gallstones"[All Fields] OR ("gall"[All Fields] AND "stones"[All Fields]) OR "gall stones"[All Fields] OR "bilestone"[All Fields] OR ("gallstones"[MeSH Terms] OR "gallstones"[All Fields] OR ("biliary"[All Fields] AND "calculus"[All Fields]) OR "biliary calculus"[All Fields]) OR ("urinary bladder calculi"[MeSH Terms] OR ("urinary"[All Fields] AND "bladder"[All Fields] AND "calculi"[All Fields]) OR "urinary bladder calculi"[All Fields] OR "cystolith"[All Fields] OR "cystoliths"[All Fields]) OR ("calculi"[MeSH Terms] OR "calculi"[All Fields] OR "concretion"[All Fields] OR "concretions"[All Fields]) OR ("cholelithiasis"[MeSH Terms] OR "cholelithiasis"[All Fields] OR "cholelithiases"[All Fields]) OR ("extra-intestinal"[All Fields] AND ("manifest"[All Fields] OR "manifestating"[All Fields] OR "manifestation"[All Fields] OR "manifestations"[All Fields] OR "manifested"[All Fields] OR "manifesting"[All Fields] OR "manifestion"[All Fields] OR "manifestions"[All Fields] OR "manifests"[All Fields]))) |
| Cochrane | (Crohn* disease OR IBD OR inflamm * bowel) AND (gall stones OR bilestone OR biliary calculus OR cystolith OR concretion OR cholelithiasis OR extra-intestinal manifestation) |
| Google Scholar | (Crohn* disease OR IBD OR inflamm * bowel) AND (gall stones OR bilestone OR biliary calculus OR cystolith OR concretion OR cholelithiasis OR extra-intestinal manifestation) |
Figure 1Summary of the study selection process according to PRISMA guidelines
PRISMA: Preferred Reporting Items for Systematic Review and Meta-Analyses
Basic characteristics of the selected studies
UC, ulcerative colitis; CD, Crohn's disease; IBD, inflammatory bowel disease
| Study Name | Year | Study design | Country | Basis of Diagnosis | Mean Age (years) | Female IBD patients (%) | No. IBD Patients (n) | No. Controls (Non-IBD) (n) | Odds Ratio (95% CI) | P value | NOS score |
| Whorwell et al. [ | 1984 | Case-control | United Kingdom | Medical records | 53 | 63.16 | 38 | 38 | 6.07 (1.56-23.55) | 0.0092 | 7 |
| Lorusso et al. [ | 1990 | Case-control | Italy | Medical records | 41 (UC) 39 (CD) | 40.3 | 159 | 2453 | 1.11 (0.66- 1.87) | 0.6967 | 9 |
| Lapidus et al. [ | 1999 | Cohort | Sweden | Medical records | N/A* | 57.3 | 131 | 556 | 2.42 (1.55-3.76) | 0.0001 | 8 |
| Bargiggia et al. [ | 2003 | Cohort | Italy | Medical records | 38 (CD) 39 (UC) | 48.5 | 511 | 145 | 2.25 (1.05-4.82) | 0.0379 | 9 |
| Parente et al. [ | 2007 | Case-control | Italy | Medical records | 34.7 (CD) 38.7 (UC) | 45.5 | 600 | 600 | 1.80 (1.14- 2.84) | 0.0110 | 9 |
| Ha et al. [ | 2015 | Cohort | Republic of Korea | Medical records | 42.66 | 50.6 | 87 | 261 | 5.06 (1.99, 12.84) | 0.0006 | 9 |
| Jeong et al. [ | 2017 | Cohort | Republic of Korea | Medical records | 47.7 | 43.4 | 311 | 622 | 2.18 (1.22-3.88) | 0.0083 | 9 |
| Chen et al. [ | 2018 | Cohort | Taiwan | ICD-9 codes | 47.7 | 52.6 | 8186 | 8186 | 1.47 (1.22-1.78) | 0.0001 | 9 |
| Yang et al. [ | 2018 | Cross-sectional | Republic of Korea | ICD-10 codes | 34 (CD) 45.7 (UC) | 36.5(CD) 41.9(UC) | 43,281 | 1,127,261 | 2.08 (1.92-2.26) | 0.0000 | 9 |
| Sturdik et al. [ | 2019 | Case-control | Slovak Republic | Medical records | 40 | 47.9 | 238 | 238 | 1.42 (0.79-2.53) | 0.2414 | 8 |
Figure 2Funnel plot for publication bias
Details of Newcastle-Ottawa Scale for observational studies
| Studies | Selection (Maximum 4) | Comparability (Maximum 2) | Outcome (Maximum 3) | Total score | |||||
| Representativeness of the Exposed Cohort | Selection of the Non-Exposed Cohort | Ascertainment of Exposure | Demonstration That Outcome of Interest Was Not Present at Start of Study | Comparability of Cohorts on the Basis of the Design or Analysis | Assessment of Outcome | Was Follow-Up Long Enough for Outcomes to Occur | Adequacy of Follow Up of Cohorts | ||
| Lapidus et al. [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Bargiggia et al. [ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Ha et al. [ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Jeong et al. [ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Chen et al. [ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Whorwell et al. [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Lorusso et al. [ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Parente et al. [ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Sturdik et al. [ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Yang et al. [ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
Figure 3Forest plot summarizing analysis of prevalence of gallstone in patients with ulcerative colitis
95% CI, 95% confidence interval
Figure 4Forest plot summarizing analysis of prevalence of gallstone in patients with Crohn’s disease
95% CI, 95% confidence interval
Figure 5Forest plot summarizing analysis of prevalence of gallstones in Asia and Europe
95% CI, 95% confidence interval